SAFETY OF SUBSEQUENT BIOLOGIC THERAPY IN RA PATIENTS WHO DISCONTINUED RITUXIMAB

被引：0
|
作者：
Genovese, Mark C. [1 ]
Breedveld, Ferdinand C. [2 ]
Emery, Paul [3 ]
Cohen, Stanley B. [4 ]
Keystone, Edward [5 ]
Matteson, Eric L. [6 ]
Burke, Laura [7 ]
Chai, Akiko [8 ]
Reiss, William [8 ]
Sweetser, Marianne [9 ]
Shaw, Tim [7 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Leiden Univ, Leiden, Netherlands
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Metroplex Clin Res Ctr, Dallas, TX USA
[5] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[6] Mayo Clin, Rochester, MN USA
[7] Roche, Prod Dev, Welwyn Garden City, Herts, England
[8] Genentech Inc, Stat, San Francisco, CA 94080 USA
[9] Biogen Idec Inc, Drug Safety, Cambridge, MA USA
来源：
RHEUMATOLOGY | 2011年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: a secondary analysis of the AVERROES trial
    Eikelboom, J.
    Synhorst, D.
    Wright, R.
    Wang, L.
    Afzal, R.
    Yusuf, S.
    Connolly, S. J.
    EUROPEAN HEART JOURNAL, 2011, 32 : 465 - 465
  • [42] Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis
    Passamonti, Francesco
    Lou, Youbei
    Chevli, Manoj
    Abraham, Pranav
    FUTURE ONCOLOGY, 2024, 20 (17) : 1165 - 1174
  • [43] Exposure of RA patients to low-dose medical radiation: impact of biologic therapy
    Murphy, G.
    Stack, J.
    O'Connell, O.
    Maher, M.
    Shanahan, F.
    Ryan, J.
    Harney, S.
    Molloy, M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S187 - S187
  • [44] EFFECT OF RF AND ACPA NEGATIVATION IN CLINICAL RESPONSE IN RA PATIENTS UNDER BIOLOGIC THERAPY
    Ganhao, Sara
    Ferreira, Raquel
    Fernandes, Bruno Miguel
    Garcia, Salome
    Mariz, Eva
    Bernardes, Miguel
    Costa, Lucia
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1581 - 1581
  • [45] Does disease activity at start of biologic therapy influence productivity losses in patients with RA?
    Johansson, K.
    Olofsson, T.
    Eriksson, J.
    van Vollenhoven, R.
    Miller, H.
    Peterson, I.
    Askling, J.
    Neovius, M.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 2 - 3
  • [46] Safety of I-131 tositumomabin in lymphoma patients who are intolerant of rituximab
    Bixby, D. L.
    Shepard, D. D.
    Rogers, K.
    Avram, A. M.
    Kaminski, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] DOES DISEASE ACTIVITY AT START OF BIOLOGIC THERAPY INFLUENCE PRODUCTIVITY LOSSES IN PATIENTS WITH RA?
    Johansson, K.
    Olofsson, T.
    Eriksson, J.
    van Vollenhoven, R.
    Miller, H.
    Petersson, I.
    Askling, J.
    Neovius, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 456 - 456
  • [48] COMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING A BIOLOGIC MONOTHERAPY AND BIOLOGIC COMBINATION THERAPY IN THE UNITED STATES
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baynton, E.
    VALUE IN HEALTH, 2014, 17 (03) : A55 - A55
  • [49] CEREBRAL TOXOPLASMOSIS IN A RA PATIENT RECEIVING BIOLOGIC THERAPY
    Gomez, Alina Sanda
    Madathil, Afsar
    Gkrania-Klotsas, Effrossyni
    Makkuni, Damodar
    RHEUMATOLOGY, 2019, 58 : 89 - 89
  • [50] Rituximab in RA:: Efficacy and safety from a randomised, controlled trial
    Stahl, HD
    Szczepañski, L
    Szechiñski, J
    Filipowicz-Sosnowska, A
    Edwards, JCW
    Close, DR
    Stevens, RM
    Shaw, TM
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 65 - 65
12345